Group 1: Investor Relations Activity Overview - The company held an earnings briefing on April 29, 2025, via the China Securities Roadshow Center [3] - Participants included the chairman, general manager, and other key executives [3] Group 2: Key Discussion Points - The earnings briefing included a video interpretation of the annual report and addressed investor concerns [4] - The company is currently upgrading its fundraising project from producing 198 tons of pharmaceutical intermediates to 420 tons of active pharmaceutical ingredients [5] - The company has established a governance structure to protect minority shareholders' interests, ensuring their participation in decision-making [5] Group 3: Future Investment Plans - The company plans to invest a total of 708 million CNY in the revised fundraising project, with 110 million CNY from raised funds and 400 million CNY from bank loans [6] - The remaining funds will be sourced from the company's own resources [6] Group 4: Customer Acquisition Strategies - The company acquires customers through various methods, including participation in trade shows, online promotion, and direct outreach [6] - The company does not have overseas assets or operations [6]
峆一药业(430478) - 投资者关系活动记录表